News Articles and Montana BioScience Alliance Newsletters
Gaize, Inc. has announced the launch of their impairment screening solution for cannabis and other drugs. The product is a first-of-its-kind fully automated, non-invasive and portable eye movement test. It’s an objective way to detect the involuntary eye movement changes associated with impairment. Gaize recently completed the world’s largest cannabis impairment clinical trial, which validated the effectiveness of the product.
Alercell has launched a new website—Lena Diagnostics, www.lenadx.com—dedicated to proprietary tests focused on early detection of cancer and leukemia.
A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine.
For over 20 years Golden Helix has been a software company that innovates genetic analysis software for next-generation sequencing (NGS) – and, believing that its customers and employees are at the heart of its success, it has built a glowing reputation as the industry leader in its field.
Inimmune is a leader in the discovery and development of vaccine adjuvants with over 20 years of expertise in their safe and effective use.
Members of the Montana BioScience Alliance are encouraged to explore the Montana Rural Health Initiative—a significant statewide investment focused on rural care delivery, workforce development, telehealth, and applied clinical innovation. This program offers Alliance companies and research partners a rare chance to access non-dilutive funding, pilot technologies in real clinical settings, and build direct partnerships with Montana healthcare systems and community stakeholders. Just as importantly, it creates a pathway to demonstrate impact while advancing commercialization inside Montana. Backed by the administration of Greg Gianforte, the initiative aligns […]
When her husband was undergoing cancer treatment, Cindy Perez of Southwest Ranches, Fla., learned about a new blood test that could help find early cancers. The 50-year-old said she felt fine, but her husband urged her to take the test anyway.
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.
Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR
Members of the Montana BioScience Alliance are encouraged to explore the Montana Rural Health Initiative—a significant statewide investment focused on rural care delivery, workforce development, telehealth, and applied clinical innovation. This program offers Alliance companies and research partners a rare chance to access non-dilutive funding, pilot technologies in real clinical settings, and build direct partnerships with Montana healthcare systems and community stakeholders. Just as importantly, it creates a pathway to demonstrate impact while advancing commercialization inside Montana. Backed by the administration of Greg Gianforte, the initiative aligns […]
View the December BIOWire Newsletter now!